For Theravance, A Big Year Gets Off To A Strong Start
Executive Summary
Theravance could soon have its first substantial revenue generator on the market, the COPD therapy Breo Ellipta partnered with GlaxoSmithKline. The launch of Breo is just one of several catalysts expected to unfold for the biotech in 2013.
You may also be interested in...
Roche’s Kadcyla, Bayer’s Xofigo Head Latest Positive Opinions In Europe
GSK’s once-daily combination inhaler Relvar Ellipta along with J&J’s diabetes therapy Invokana, Novo Nordisk’s hemophilia therapy NovoEight and Gilead HIV therapy Vitekta complete the list of six new medicines recommended for approval by the CHMP, Europe’s top scientific advisory panel.
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.
Theravance To Split Into A Royalty Play and An R&D Company
With a pair of PDUFA dates this year, Theravance is thinking ahead how to pass potential royalties to investors while continuing to fund its pipeline. The biopharma said it would separate into two public companies: a royalty play to return cash to shareholders and an R&D pipeline story.